Publication Name	World Journal of Gastroenterology
Manuscript ID	20496
Country	Canada

Received	2015-06-08 08:46
Peer-Review Started	2015-06-10 08:27
To Make the First Decision	2015-07-14 12:00
Return for Revision	2015-07-27 19:42
Revised	2015-08-12 01:44
Second Decision	2015-10-23 16:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-11-09 17:24
Articles in Press	2015-11-09 17:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-11 12:30
Publish the Manuscript Online	2015-12-31 13:27

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Combination antiretroviral studies for patients with primary biliary cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Ellina Lytvyak, Aldo J Montano-Loza and Andrew L Mason
Funding Agency and Grant Number	Funding Agency Grant Number Alberta Innovates Health Solutions, Canadian Institutes for Health Research MOP 97798 (to Mason AL) Canadian Liver Foundation
Corresponding Author	Andrew L Mason, MBBS, FRCPI, Professor of Medicine, Division of Gastroenterology and Hepa­tology, University of Alberta, 7-142 Katz Group Rexall Centre, Edmonton T6G 2E1, Alberta, Canada. andrew.mason@ualberta.ca
Key Words	Primary biliary cirrhosis; Antiretroviral therapy; Human betaretrovirus; Randomized controlled trial; Endpoints for trials
Core Tip	Early experience with antiretroviral therapy in primary biliary cirrhosis (PBC) patients strongly suggests that reverse transcriptase inhibitors alone lack efficacy to provide sustained and clinically meaningful biochemical responses. In contrast, combination antiretroviral therapy with human immunodeficiency virus protease inhibitors have been linked with robust and long-lived biochemical responses in PBC patients capable of tolerating the therapy. The use of digital droplet polymerase chain reaction has markedly improved the sensitivity of viral detection in peripheral blood and should enable studies to link reduction in viral load with improvements in hepatic biochemistry and histology.
Publish Date	2015-12-31 13:27
Citation	Lytvyak E, Montano-Loza AJ, Mason AL. Combination antiretroviral studies for patients with primary biliary cirrhosis. World J Gastroenterol 2016; 22(1): 349-360
URL	http://www.wjgnet.com/1007-9327/full/v22/i1/349.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i1.349

Full Article (PDF)	WJG-22-349.pdf
Full Article (Word)	WJG-22-349.doc
Manuscript File	20496-Review.docx
Answering Reviewers	20496-Answering reviewers.pdf
Audio Core Tip	20496-Audio core tip.wma
Conflict-of-Interest Disclosure Form	20496-Conflict-of-interest statement.pdf
Copyright License Agreement	20496-Copyright assignment.pdf
Peer-review Report	20496-Peer-review(s).pdf
Scientific Misconduct Check	20496-Scientific misconduct check.pdf
Scientific Editor Work List	20496-Scientific editor work list.pdf